We used cryo-EM to image tau filaments extracted from the frontotemporal cortex of a patient who had a 7 year history of behavioural-variant frontotemporal dementia (patient 4). Neuropathological examination revealed severe frontotemporal lobar degeneration, with abundant Pick bodies composed of 3R tau filaments, without phosphorylation of S~262~ ([Fig. 1a-d](#F1){ref-type="fig"}, [Extended Data Fig. 1](#F4){ref-type="fig"}, [Extended Data Table 1](#T1){ref-type="table"}), consistent with a diagnosis of Pick's disease.^[@R12]--[@R17]^ As in Alzheimer's disease^[@R18]^, a fuzzy coat composed of the disordered N- and C-terminal regions of tau surrounded the filament cores and was removed by pronase treatment ([Fig. 1e](#F1){ref-type="fig"} and [Extended Data Fig. 1](#F4){ref-type="fig"}). Narrow (93%) and wide (7%) filaments could be distinguished ([Fig. 1e](#F1){ref-type="fig"}). The narrow filaments have previously been described as straight^[@R19]--[@R21]^, but they do have a helical twist with a cross-over distance of \~1000 Å and a projected width varying from approximately 50 to 150 Å. The wide filaments have a similar cross-over distance, but their width varies from approximately 50 to 300 Å. We named them narrow and wide Pick filaments (NPFs and WPFs). Their morphologies and relative abundance match those reported in cortical biopsies from Pick's disease brain ^[@R21]^.

Using helical reconstruction in RELION^[@R22]^, we determined a 3.2 Å resolution map of the ordered core of NPFs, in which side-chain densities were well resolved and β-strands were clearly separated along the helical axis ([Fig. 1f](#F1){ref-type="fig"} and [Extended Data Fig. 2](#F5){ref-type="fig"}). We also determined a map of WPFs, which was limited to 8 Å resolution because of the small number of filaments. This was sufficient to show separated β-sheets within the structure, but not the 4.7 Å spacing of individual β-strands along the helical axis ([Fig. 1g](#F1){ref-type="fig"} and [Extended Data Fig. 3](#F6){ref-type="fig"}). NPFs are composed of a single protofilament with an elongated structure that is markedly different from the C-shaped protofilament of Alzheimer's disease paired helical and straight filaments (PHFs and SFs)^[@R11],[@R23]^. WPFs are formed by the association of two NPF protofilaments at their distal tips. In support, we observed WPFs where one protofilament had been lost in some parts ([Extended Data Fig. 3](#F6){ref-type="fig"}). Our results reveal that the tau filaments of Pick's disease adopt a single fold that is different from that of the tau filaments of Alzheimer's disease.

The high-resolution NPF map allowed us to build an atomic model of the Pick tau filament fold, which consists of residues K~254~-F~378~ of 3R tau (in the numbering of the 441 amino acid human tau isoform) ([Fig. 2](#F2){ref-type="fig"}). There are nine β-strands (β1--9) arranged into four cross-β packing stacks and connected by turns and arcs (Fig. 3a,b). R1 provides two strands, β1 and β2, and R3 and R4 provide three strands each, β3--5 and β6--8, respectively. These pack together in a hairpin-like fashion: β1 against β8, β2 against β7, β3 against β6 and β4 against β5. The final strand, β9, is formed from 9 amino acids after R4 and packs against the opposite side of β8. Only the interface between β3 and β6 is entirely hydrophobic; the other cross-β packing interfaces are composed of both non-polar and polar side-chains.

The inter-strand connections and their interactions maintain the strand pairings and compensate for differences in strand lengths and orientations. A sharp right-angle turn at G~261~, between β1 and β2, faces a smooth four-residue arc formed of ~355~GSLD~358~, between β7 and β8, turning the protein chain in the same direction. The ~270~PGGG~273~ motif between β2 and β3 gives rise to an omega-shaped turn that compacts the protein chain locally, but maintains its direction at either end. On the opposite side, a β-arc formed of E~342~ and K~343~, between β6 and β7, creates space for this turn. In contrast, the homologous ~332~PGGG~335~ motif connecting β5 and β6 forms an extended β-spiral conformation, compensating for the shorter lengths of these strands compared to the opposing β3 and β4, which are connected by P~312~. Solvent-mediated interactions may occur within the large cavity between this motif and the side-chains at the junction of β3 and β4. The third homologous ~364~PGGG~367~ motif contributes to a 180° turn that allows β9 to pack against the other side of β8. Variations in the height of the chain along the helical axis also help to maintain an ordered hydrogen-bonding pattern of the β-stranded regions ([Fig 3c](#F3){ref-type="fig"}).

The solvent-exposed side-chains of C~322~ and S~324~, together with the intervening G~323~, form a flat surface at the hairpin-turn between β4 and β5. This provides the interface for the formation of WPFs by abutting of protofilaments ([Extended Data Fig. 3](#F6){ref-type="fig"}). The distances between protofilaments at this interface would enable van der Waals interactions, but not disulfide bond formation. In support, WPFs were stable under reducing conditions ([Extended Data Fig. 3](#F6){ref-type="fig"}). At the resolution of the WPF map, it was not possible to determine if protofilament β-strands are aligned or staggered by one half the β-strand distance, as is the case for PHFs in Alzheimer's disease^[@R11]^. We conclude that WPFs are formed by two separate protofilaments making tight contacts at their distal tips through van der Waals interactions.

Three regions of less well-resolved density bordering the solvent-exposed faces of β4, β5 and β9 are apparent in the unsharpened maps of both NPFs and WPFs ([Fig. 1f,g](#F1){ref-type="fig"}). Their low-resolution suggests that they represent less ordered, heterogeneous and/or transiently occupied structures. The density bordering β4 is similarly located, but more extended and less-well resolved, than that found to interact with the side-chains of K~317~, T~319~ and K~321~ in Alzheimer's disease PHFs and SFs^[@R11]^, and hypothesized to be the N-terminal ~7~EFE~9~, part of the discontinuous MC1 epitope^[@R24]^. NPFs and WPFs were labelled by MC1 ([Extended Data Fig. 1](#F4){ref-type="fig"}).

It was not previously known why only 3R tau, which lacks the second microtubule-binding repeat, is present in Pick body filaments. Our results suggest that despite sequence homology, the structure formed by K~254~-K~274~ of the first tau repeat is inaccessible to the corresponding residues from the second repeat of 4R tau (S~285~-S~305~). The site occupied by T~263~, which is in close proximity to the backbone of the opposite strand β7, cannot accommodate the bulkier side-chain of K~294~ from 4R tau and does not provide a favourable environment for its charged ε-amino group ([Extended Data Fig. 4](#F7){ref-type="fig"}). Also, the site preceding the omega-like structure formed by ~270~PGGG~273~ cannot accommodate a Cβ branched residue, such as V~300~ from 4R tau instead of Q~269~ from 3R tau. In addition, the smaller C~291~ residue from 4R tau would form weaker interactions with L~357~ and I~360~ than those formed by I~260~ of 3R tau. In support, tau filaments extracted from the brain of the patient with Pick's disease used for cryo-EM seeded the aggregation of recombinant full-length 3R, but not 4R, tau ([Extended Data Fig. 5](#F8){ref-type="fig"}). Similar experiments have shown that Alzheimer's disease PHFs and SFs, whose core sequences are shared by 3R and 4R tau, can seed both types of isoform^[@R25]^. Such templated misfolding explains the selective incorporation of 3R tau in Pick body filaments. Pick's disease extracts have been reported to seed the aggregation of a 4R tau fragment comprising the repeats (residues 244--372) with mutations P301L and V337M^[@R26]^. However, this tau fragment cannot form the Pick fold, which is unable to accommodate R2 and requires residues 373--378. A small amount of aggregated four-repeat tau may have accounted for the seeding activity, as suggested in a separate study^[@R8]^. Loss of von Economo neurons in anterior cingulate and frontoinsular cortices has been reported to be an early event in Pick's disease^[@R27],[@R28]^. It remains to be established how 3R tau seeds can form in cells that also express 4R tau. Alternatively, nerve cell populations may be distinguished by the tau isoforms that they express^[@R29]^.

The cryo-EM structures presented here were derived from filaments that were extracted from the brain of a single patient with Pick's disease (patient 4). To test the generality of the Pick fold, we investigated the binding of repeat-specific antibodies to tau filaments extracted from the frontotemporal cortex of eight additional patients with sporadic Pick's disease ([Extended Data Table 1](#T1){ref-type="table"}). By Western blotting, all samples ran as two tau bands of 60 and 64 kDa, which were detected by anti-R1, -R3 and -R4 antibodies, but not by an anti-R2 antibody, showing the presence of only 3R tau ([Extended Data Fig. 6](#F9){ref-type="fig"}). Immunogold negative-stain electron microscopy showed that most filaments were NPFs, with a minority of WPFs, and were not decorated by the repeat-specific antibodies ([Extended Data Fig. 7](#F10){ref-type="fig"}). This shows that the R1, R3 and R4 epitopes are inaccessible to the antibodies used, indicating that they form part of the ordered filament core. Alzheimer's disease PHFs and SFs are decorated by anti-R2, but not by anti-R3 and -R4 antibodies, because their core is made of R3, R4 and the 10 amino acids following R4^[@R11],[@R30]^. These results are in good agreement with experiments using limited proteolysis and mass-spectrometry^[@R7]^. We conclude that the ordered core of tau filaments from Pick's disease comprises the C-terminal part of R1, all of R3 and R4, as well as 10 amino acids after R4.

Unlike Alzheimer's disease PHFs and SFs, Pick body filaments are not phosphorylated at S~262~ and/or S~356~ ([Extended Data Fig. 1](#F4){ref-type="fig"})^[@R14],[@R16]^. The reasons for this differential phosphorylation are unknown. Our structure reveals that the tight turn at G~261~ prevents phosphorylation of S~262~ in the ordered core of Pick's disease filaments, whereas the phosphorylated S~262~ is outside the ordered core of Alzheimer's disease filaments^[@R11]^. This explains the differential phosphorylation and raises the question of whether phosphorylation at S~262~ may protect against Pick's disease.

In the Pick and Alzheimer tau filament folds, most β-structure residues between V~306~ and I~354~ align locally, as do the connecting segments of P~312~, ~332~PGGG~335~ and ~342~EK~343~ ([Figure 3](#F3){ref-type="fig"}). Almost all amino acid side-chains from this region have the same interior or solvent-exposed orientations in both folds. Exceptions are C~322~ and D~348~, which cause reversed chain directions in one or other fold ([Figure 3d](#F3){ref-type="fig"}). The side-chain of C~322~ is interior in the Alzheimer tau filament fold, whereas it is solvent-exposed in the Pick fold. This enables the hairpin-like turn and the cross-β packing of β4 against β5. The side-chain of D~348~ is interior in the Pick tau filament fold, thereby maintaining β-structure from K~343~ to I~354~ (β7), whereas it is solvent exposed in the Alzheimer fold, enabling the tight turn between β5 and β6, which, together with β4, gives rise to a triangular β-helix conformation^[@R11]^. Such β-helices, previously thought to be important for propagation^[@R31]^, are absent from the Pick tau filament fold. The β-strands in G~355~-F~378~ align well in both folds, but have different cross-β packing arrangements. The solvent-exposed side-chains of β7 and β8 in the Alzheimer fold are interior in the equivalent strands of the Pick fold (β8 and β9), because of different conformations of the two turn regions in R4, ~355~GSLD~358~ and ~364~PGGG~367~. The ~355~GSLD~358~ motif makes a sharp right-angle turn at G~355~ in the Alzheimer tau filament fold, but a wide turn in the Pick fold. The same sharp turn is found at the homologous site in R1 in the Pick tau filament fold, whereas the same wide turn occurs at the homologous site in R3 in the Alzheimer fold ([Fig. 3](#F3){ref-type="fig"}). This suggests that these semi-conserved turn structures may also be found in tau filament folds in other diseases. In contrast, the ~364~PGGG~367~ motif adopts a new conformation in the Pick fold, which reverses the chain direction and is different from both the right-angle turn that this motif forms in the Alzheimer fold and the conformations of the homologous PGGG motifs from the other repeats in both tau filament folds. The Pick and Alzheimer folds share similar secondary structure patterns, but different turn conformations result in distinct cross- β packing.

These findings show that the ordered cores of tau filaments from Pick's disease adopt a single, novel fold of 3R tau, which is distinct from the tau filament fold of Alzheimer's disease. This suggests that different folds may account for tauopathies with 4R tau filaments, such as progressive supranuclear palsy. Our results also suggest that single, disease-specific folds may exist in tauopathies with the same tau filament isoform composition, such as progressive supranuclear palsy and corticobasal degeneration, since identical tau sequences can adopt more than one fold. Conserved secondary structure motifs and markedly different conformations at turn residues in the Alzheimer and Pick tau filament folds may form the basis for structural diversity in tau protein folds from other neurodegenerative diseases. The structures of different tau filament folds will provide the basis for determining the binding sites of tau ligands and give a rationale for their interactions with inclusions in different tauopathies^[@R32]^.

The identification of disease-specific folds in the ordered cores of tau filaments establishes the existence of molecular conformers. This is central to the hypothesis that conformers of filamentous tau give rise to the clinical phenotypes that define distinct tauopathies, akin to prion strains. By revealing the structural basis for molecular conformers in specific diseases, our results pave the way to a better understanding of a wide range of diseases related to abnormal protein aggregation.

Methods {#S1}
=======

Extraction of tau filaments {#S2}
---------------------------

Sarkosyl-insoluble material was extracted from grey matter of frontal and temporal cortex of the patients' brains, as described^[@R33]^. Approximately 6 g tissue was used for cryo-EM and 0.6 g tissue was used for immunolabelling. The pelleted sarkosyl-insoluble material was resuspended in 50mM Tris-HCl pH 7.4 containing 150mM NaCl and 0.02% amphipol A8--35 at 250 μl per g tissue, followed by centrifugation at 3,000 ×*g* for 30min at 4°C. The pellets, containing large contaminants, were discarded. The supernatants were centrifuged at 100,000 ×*g* for 30 min at 4°C. The resulting pellets were resuspended in buffer at 15 μl per g tissue for cryo-EM and 150 μl per g tissue for immunolabelling. Pronase treatment was carried out as described for negative-stain EM^[@R33]^ and cryo-EM^[@R11]^. Tau filaments were incubated with 0.4 mg/ml pronase (Sigma) for 5 min at 21°C before being deposited on EM grids and plunge-frozen.

Cloning and purification of epitope-deletion Recombinant tau {#S3}
------------------------------------------------------------

Tau constructs lacking the BR136, Anti-4R, BR135 and TauC4 peptide sequences were cloned from pRK172 encoding wild-type 0N4R or 2N4R tau using the QuikChange Lightning site-directed mutagenesis kit (Agilent), according to the manufacturer's instructions. All recombinant tau proteins were expressed and purified as described^[@R34]^.

Immunolabelling and histology {#S4}
-----------------------------

Western blotting and immunogold negative-stain EM were carried out as described^[@R33]^. For Western blotting, samples were resolved on 4--20% or 10% Tris-glycine gels (Novex), and the primary antibodies were diluted in PBS plus 0.1% Tween 20 and 1% BSA. BR136 is a polyclonal antibody that was raised against a synthetic peptide corresponding to residues 244--257 of tau. The peptide (200 μg), coupled to keyhole limpet hemocyanin using glutaraldehyde, was mixed 1:1 with Freund's complete adjuvant and used to immunise white Dutch rabbits. Booster injections using 200 μg of conjugated peptide mixed 1:1 with Freund's incomplete adjuvant were given every 2 weeks for 10 weeks following the primary immunisation. Antibodies were harvested 7 days after the final booster injection and affinity purified. [Extended Data Figure 6](#F9){ref-type="fig"} shows that BR136 is specific for the C-terminal region of residues 244--257. Neurohistology and immunohistochemistry were carried out as described^[@R35]^. Brain sections were 8μm thick and were counterstained with haematoxylin. Detailed antibody information is provided in [Extended Data Table 2](#T2){ref-type="table"}.

Whole exome sequencing {#S5}
----------------------

Whole exome sequencing was carried out at the Center for Medical Genomics of Indiana University School of Medicine using genomic DNA from the nine individuals with neuropathologically confirmed diagnoses of Pick's disease, the tau filaments of which were used in Extended Data Figures [6](#F9){ref-type="fig"} and [7](#F10){ref-type="fig"}. Target enrichment was performed using the SureSelectXT human all exon library (V6, 58Mb, Agilent) and high-throughput sequencing using a HiSeq4000 (2×75bp paired-end configuration, Illumina). Bioinformatics analyses were performed as described^[@R36]^. Findings on *MAPT*, *PSEN1* and *APOE* are presented in [Extended Data Table 1](#T1){ref-type="table"}.

Seeded aggregation {#S6}
------------------

Seeded aggregation was carried out as described^[@R37]^, but with full-length wild-type tau protein and without the aggregation inducer heparin. Recombinant 0N3R and 0N4R tau were purified as described^[@R34]^. Extracted tau filaments (15 μl per g tissue) were diluted 1:10 in 10 mM HEPES pH7.4, 200 mM NaCl; 2 μl was added to 98 μl of 20 μM 0N3R or 0N4R recombinant tau in the same buffer with 10 μM thioflavin T in a black, clear bottom 96-well plate (Perkin Elmer). The plate was sealed and incubated at 37°C in a plate reader (BMG Labtech FLUOstar Omega), with cycles of shaking for 60s (500 rpm, orbital) followed by no shaking for 60 s. Filament formation was monitored by measuring Thioflavin T fluorescence every 45 min using 450 −10 nm excitation and 480 −10 nm emission wavelengths, with an instrument gain of 1100. Three independent experiments were performed with separate recombinant protein preparations.

Electron cryo-microscopy {#S7}
------------------------

Extracted, pronase-treated tau filaments (3μl at a concentration of \~0.5mg/ml) were applied to glow-discharged holey carbon grids (Quantifoil Au R1.2/1.3, 300 mesh) and plunge-frozen in liquid ethane using an FEI Vitrobot Mark IV. Images were acquired on a Gatan K2-Summit detector in counting mode using an FEI Titan Krios at 300kV. A GIF-quantum energy filter (Gatan) was used with a slit width of 20eV to remove inelastically scattered electrons. Fifty-two movie frames were recorded, each with an exposure time of 250ms using a dose rate of 1.06 electrons per Å^2^ per frame for a total accumulated dose of 55 electrons per Å^2^ at a pixel size of 1.15Å on the specimen. Defocus values ranged from −1.7 to −2.8μm. Further details are presented in [Exended Data Table 3](#T3){ref-type="table"}.

Helical reconstruction {#S8}
----------------------

Movie frames were corrected for gain reference, motion-corrected and dose-weighted using MOTIONCOR2^[@R38]^. Aligned, non-dose-weighted micrographs were used to estimate the contrast transfer function (CTF) in Gctf^[@R39]^. All subsequent image-processing steps were performed using helical reconstruction methods in RELION 2.1^[@R22],[@R40]^. NPFs and WPFs were picked manually and processed as separate datasets.

### NPF dataset {#S9}

NPF segments were extracted using a box size of 270 pixels and an inter-box distance of \~10% of the box size. Reference-free 2D classification was performed using a regularization value of T=2, and segments contributing to suboptimal 2D class averages were discarded. An initial helical twist of −0.73° was estimated from the crossover distances of NPFs in micrographs, and the helical rise was estimated to be 4.7 Å. Using these values, an initial 3D reference was reconstructed *de novo* from 2D class averages of segments comprising an entire helical cross-over. A first round of 3D classification, starting from the *de novo* initial model low-pass filtered to 40 Å, with local optimization of the helical twist and rise, and a regularization value of T=4 yielded a reconstruction in which individual β-sheets perpendicular to the helical axis were clearly separated, but no structure was discernable along the helical axis. Subsequently, 3D auto-refinement with optimization of helical twist and rise and a regularization value of T = 10 was performed using the segments that contributed to the 3D class displaying β-sheets. The resulting reconstruction showed clearly discernable β-strand separation.

An additional round of 3D classification with a regularization value of T = 10 starting from the 5 Å low-pass filtered map from the previous auto-refinement was used to further select segments for a final high-resolution refinement. In total, 16,097 segments contributed to the final map. The reconstruction obtained with this relatively small subset of the initial dataset matched lower-resolution reconstructions obtained with larger subsets of the data, indicating that image classification did not select for a specific structure from a conformationally heterogeneous dataset, but instead was successful in distinguishing the segments with high-resolution information from images of varying quality. This is in line with observations in single-particle analysis^[@R41]^. Superimposing the selected segments onto the original micrographs further confirmed this. Image classification also did not separate filaments with variable twists; instead, RELION combines segments from filaments with variable twists into a single 3D reconstruction and reduces the corresponding blurring effects by only using the central part of an intermediate asymmetrical reconstruction for real-space helical symmetrisation^[@R22]^. We used a 10% value for the corresponding helical z_percentage parameter.

Optimization of the helical twist and rise converged onto −0.75° and 4.78Å, respectively. Refinements with helical rises of multiples of 4.78Å all led to β-strand separation, but in agreement with the observed absence of layer lines between 50 and 4.7Å we were unable to detect any repeating patterns along the helical axis other than the successive rungs of β-strands.

The final NPF reconstruction was sharpened using standard post-processing procedures in RELION, resulting in a B-factor of −57Å^2^ ([Extended Data Table 3](#T3){ref-type="table"}). Helical symmetry was imposed on the post-processed map using RELION helix toolbox^[@R22]^. Final, overall resolution estimates were calculated from Fourier shell correlations at 0.143 between the two independently refined half-maps, using phase-randomization to correct for convolution effects of a generous, soft-edged solvent mask^[@R42]^. The overall resolution estimate of the final map was 3.2 Å. Local resolution estimates were obtained using the same phase-randomization procedure, but with a soft spherical mask that was moved over the entire map.

### WPF dataset {#S10}

The WPF dataset was down-scaled to a pixel size of 3.45 Å and segments were extracted using a box size of 180 pixels and an inter-box distance of \~10% of the box size. As with the NPF dataset, an initial 3D reference was reconstructed *de novo* from 2D class averages of segments comprising an entire helical cross-over. 3D classification was then performed to discard suboptimal segments. 3D auto-refinement of the best class with a regularization value of T = 4 and a fixed helical rise and twist of 4.7Å and −0.6°, respectively, led to a 3D structure with good separation of β-sheets perpendicular to the helical axis, but no structure was discernable along the helical axis. The cross-section of this map clearly revealed the presence of two NPF protofilaments. To further improve the reconstruction, we also made an initial model by placing two NPF maps, rotated 180° relative to each other in the WPF reconstruction, and low-pass filtering the resulting map to 60 Å. After a second 3D auto-refinement starting from this model, the final WPF reconstruction had an estimated overall resolution of 8Å and was sharpened by specifying a b-factor of −200 Å^2^ ([Extended Data Table 3](#T3){ref-type="table"}). In total, 3,003 segments contributed to the final map.

Model building and refinement {#S11}
-----------------------------

A single monomer of the NPF core was built *de novo* in the 3.2 Å resolution reconstruction using COOT^[@R43]^. Model building was started from the distinctive extended β-spiral conformation of the ~332~PGGG~335~ motif, neighbouring the large histidine side chains of residues 329 and 330, and working towards the N- and C-terminal regions by manually adding amino acids, followed by targeted real-space refinement. This assignment of amino acids was unambiguous due to the clear densities of the three PGGG motifs and the large aromatic side chains of Y310 and F346. The model was then translated to give a stack of three consecutive monomers to preserve nearest-neighbour interactions for the middle chain in subsequent refinements using a combination of real-space refinement in PHENIX^[@R44]^ and Fourier-space refinement in REFMAC^[@R45]^. In the latter, local symmetry restraints were imposed to keep all β-strand rungs identical. Since most of the structure adopts a β-strand conformation, hydrogen-bond restraints were imposed to preserve a parallel, in-register hydrogen-bonding pattern in earlier stages of the model building process. Side-chain clashes were detected using MOLPROBITY^[@R46]^ and corrected by iterative cycles of real-space refinement in COOT and Fourier-space refinement in REFMAC. The refined model of the NPF was rigid-body fitted into the WPF map. Separate NPF model refinements were performed against a single half-map, and the resulting model was compared to the other half-map to confirm the absence of overfitting. The final model was stable in refinements without additional restraints.

Ethical Review Board and Informed Consent {#S12}
-----------------------------------------

The Indiana Alzheimer Disease Center studies were reviewed and approved by the Indiana University Institutional Review Board. Informed consent was obtained from the patients' next of kin.

Data Availability {#S13}
=================

Cryo-EM maps have been deposited in the Electron Microscopy Data Bank (accession numbers EMD-0077 for NPF and EMD-0078 for WPF). The NPF refined atomic model has been deposited in the Protein Data Bank (accession number 6GX5). Whole exome sequencing data that support the findings of this study have been deposited in the European Genome-phenome Archive (accession number EGAS00001003106).

Extended Data {#S14}
=============

![Further characterization of the filamentous tau pathology of Pick's disease\
**a,** Staining of Pick bodies in the frontotemporal cortex of patient 4 by Bodian silver and antibody AT8 (pS202 and pT205 tau), but not by Gallyas-Braak silver. Nuclei are counterstained blue. Scale bars, 20 μm. **b,c,** Immunolabeling of the tau filaments extracted from the frontotemporal cortex of patient 4. Immunoblots (**b**) with antibodies BR133 (tau amino-terminus), BR134 (tau carboxy-terminus), RD3 (3R tau), Anti-4R (4R tau), AT8 (pS202 and pT205 tau) and 12E8 (pS262 tau and/or pS356 tau). Immunogold negative-stain electron micrographs (**c**) with antibodies BR133, BR134, 12E8 and MC1 of NPFs and WPFs with and without pronase treatment. Scale bar, 500 Å.](nihms-1500333-f0004){#F4}

![Narrow Pick filament (NPF) structure\
**a,** Fourier shell correlation curves between two independently refined half-maps (black line) and between the cryo-EM reconstruction and refined atomic model (red line). **b,** Local resolution estimates for the NPF reconstruction. **c,** Helical axis views of the NPF reconstruction. **d,** Close-up views of the cryo-EM map with the atomic model overlayed. The top row shows the three PGGG motifs; the bottom row shows several amio acids with large side-chains.](nihms-1500333-f0005){#F5}

![Wide Pick filament (WPF) structure\
**a,** Fourier shell correlation curves between two independently refined half-maps. **b,** Local resolution estimates for the WPF reconstruction. **c,** WPF density at high (light grey) and low (dark grey) threshold with densities for two NPFs overlaid (yellow and blue). The atomic models fitted to the NPF densities in the region of the protofilament interface are shown in the boxed out area. **d,** Cryo-EM images showing WPFs from patient 4 (false coloured red) where segments from one of the protofilaments have been lost. Scale bar, 500 Å. **e,** Negative-stain EM images of WPFs from patient 4 following incubation in 100 mM dithiothreitol for 20 h. Scale bar, 500 Å.](nihms-1500333-f0006){#F6}

![Incompatibility of Pick tau filament fold with 4R tau\
Atomic model of Pick fold with 4R tau sequence overlaid. The region formed by K254-K274 from R1 is replaced by the S285-V300 region from R2 in 4R tau. Residues that differ between these regions of R1 and R2 are coloured orange. The major discrepancies of lysine at position 294 in R2, instead of threonine at position 263 in R1, and valine at position 300 in R2, instead of glutamine at position 269 in R1, are highlighted with dashed red outlines. The minor discrepancy of weaker interactions of C291 of R2 with L357 and I360 than those formed by I260 of R1 is highlighted with a dashed yellow outline.](nihms-1500333-f0007){#F7}

![Seeded aggregation of full-length 3R, but not 4R, tau by the sarkosyl-insoluble fraction from Pick's disease brain\
**a,** Coomassie-stained SDS-PAGE of the 0N3R and 0N4R recombinant tau preparations used for seeded aggregation. Two additional recombinant tau preparations were carried out with similar results. **b,** Thioflavin T fluorescence measurements of 0N3R (red) and 0N4R (blue) recombinant tau following incubation with (triangles) or without (circles) the sarkosyl-insoluble fraction from the frontotemporal cortex of patient 4. The results are from three independent experiments using separate recombinant protein preparations. The sarkosyl-insoluble fraction from Pick's disease brain efficiently seeded the aggregation of 3R, but not 4R, tau](nihms-1500333-f0008){#F8}

![Immunoblot analysis of additional Pick's disease cases\
**a,** Diagram of 2N4R tau showing the N-terminal inserts (N1, N2), the repeats (R1-R4) and the epitopes of antibodies BR133 (N-terminus), BR136 (R1), Anti-4R (R2), BR135 (R3), TauC4 (R4) and BR134 (C-terminus). **b,** Immunoblots of epitope-deletion recombinant tau constructs with the antibodies shown in a. Identical results were obtained in two independent repeats. **c,** Immunoblots using the antibodies BR136, Anti-4R, BR135 and TauC4 of tau filaments extracted from the frontotemporal cortex of 9 patients with Pick's disease (patient 4 was used for cryo-EM). See [Extended Data Table 1](#T1){ref-type="table"} for details of Pick's disease patients.](nihms-1500333-f0009){#F9}

![Immunogold negative-stain EM analysis of additional Pick's disease cases\
**a,** Representative immunogold negative-stain electron microscopy with antibodies BR133 (tau amino-terminus), BR136 (tau R1), Anti-4R (tau R2), BR135 (tau R3), TauC4 (tau R4) and BR134 (tau carboxy-terminus) of NPFs and WPFs extracted from the frontotemporal cortex of patient 4. Scale bars, 100 nm. Similar results were obtained with tau filaments extracted from the frontotemporal cortices of eight additional patients with Pick's disease **b,** Table summarizing results from a. Results for patient 4 (shown in a. and used for cryo-EM) are highlighted in yellow. See [Extended Data Table 1](#T1){ref-type="table"} for details of Pick's disease patients. Tick marks indicate antibody decoration of filaments, while crosses indicate that the antibodies did not decorate filaments. NPFs and WPFs were decorated by the antibodies against the N- and C-termini of tau, but not by the tau repeat-specific antibodies.](nihms-1500333-f0010){#F10}

###### Summary of Pick's disease patients

Wild-type (wt) means that no known disease-causing mutations in the tau gene (MAPT) or the presenilin-1 gene (PSEN1) were detected. The patient used for cryo-EM is highlighted in yellow.

  Patient   Gender   Age at death (years)   MAPI   PSEN1   APOE haplotypes   Post-mortem interval (h)
  --------- -------- ---------------------- ------ ------- ----------------- --------------------------
  1         F        73                     wt     wt      E3/E3             23.8
  2         F        70                     wt     wt      ɛ3/ɛ3             20.5
  3         M        61                     wt     wt      ɛ3/ɛ4             24.5
  4         F        63                     wt     wt      ɛ2/ɛ3             3.0
  5         M        70                     wt     wt      ɛ3/ɛ3             14.0
  6         M        65                     wt     wt      ɛ3/ɛ3             12.5
  7         M        64                     wt     wt      ɛ3/ɛ4             3.0
  8         M        56                     wt     wt      ɛ3/ɛ4             9.0
  9         M        69                     wt     wt      ɛ3/ɛ4             4.5

###### Primary anti-tau antibodies used in this study

Details of the primary Anti-tau antibodies used in this study. Abbreviations are WB, Western blot; EM, Immunogold negative stain electron microscopy; IHC, immunohistochemistry; TEM, immunogold negative-stain electron microscopy; WB, western blot.

  Name      Epitope                                            Supplier          Cat. number       Species   Type         WB dilution   EM dilution   IHC dilution   Validation
  --------- -------------------------------------------------- ----------------- ----------------- --------- ------------ ------------- ------------- -------------- ----------------------------------------------------
  BR133     N-terminus                                         In house          \-                Rabbit    Polyclonal   1:4,000       1:50          \-             30
  BR134     C-terminus                                         In house          \-                Rabbit    Polyclonal   1:4,000       1:50          \-             30
  BR136     R1                                                 In house          \-                Rabbit    Polyclonal   1:4,000       1:50          \-             Extended Data Fig. 6
  Anti-4R   R2                                                 Cosmo Bio         CAC-TIP-4RT-P01   Rabbit    Polyclonal   1:2,000       1:50          1:100          Manufacturer\'s datasheet and Extended Data Fig. 6
  BR135     R3                                                 In house          \-                Rabbit    Polyclonal   1:4,000       1:50          \-             ^30^ and Extended Data Fig. 6
  Tau C4    R4                                                 Masato Hasegawa   \-                Rabbit    Polyclonal   1:2,000       1:50          \-             ^7^ and Extended Data Fig. 6
  RD3       Rl/3                                               Millipore         05-803            Mouse     Monoclonal   1:4,000       \-            1:3,000        Manufacturer\'s datasheet
  12E8      pS262 and/or pS356                                 Peter Seubert     \-                Mouse     Monoclonal   1:100,000     1:50          1:1,000        ^47,48^
  AT8       pS202 and pT205                                    Thermo            MN1020            Mouse     Monoclonal   1:1,000       1:50          1:300          Manufacturer\'s datasheet
  MCI       Discontinuous epitope (residues 7-9 and 313-322)   Peter Davies      \-                Mouse     Monoclonal   \-            1:10          \-             ^24^

###### Cryo-EM data collection, refinement and validation statistics

                                       NPF (EMDB-0077) (PDB 6GX5)   WPF (EMDB-0078)
  ------------------------------------ ---------------------------- -----------------
  **Data collection and processing**                                
  Magnification                        x105,000                     x105,000
  Voltage (kV)                         300                          300
  Electron exposure (e-/Å^2^)          55                           55
  Defocus range (μ)                    −1.7 to −2.8                 −1.7 to −2.8
  Pixel size (Å)                       1.15                         3.45
  Symmetry imposed                     None                         C2
  Initial particle images (no.)        83,475                       8,024
  Final particle images (no.)          16,097                       3,003
  Map resolution (Å)                   3.2                          8
    FSC threshold                      0.143                        0.143
  Map resolution range (Å)             3.2 to 3.5                   8 to 12
  Helical rise (Å)                     4.78                         4.7
  Helical twist (Å)                    −0.75                        −0.6
  **Refinement**                                                    
  Initial model used (PDB code)        *de novo*                    n/a
  Model resolution (Å)                 3.2                          n/a
    FSC threshold                      0.5                          
  Model resolution range (Å)           3.2                          n/a
  Map sharpening *B* factor (A^2^)     −57                          −200
  Model composition                                                 n/a
    Non-hydrogen atoms                 2133                         
    Protein residues                   282                          
    Ligands                            0                            
  *B* factors (Å^2^)                                                n/a
    Protein                            75.8 average                 
    Ligand                             n/a                          
  R.m.s. deviations                                                 n/a
    Bond lengths (Å)                   0.0175                       
    Bond angles (Å)                    1.1678                       
  Validation                                                        n/a
    MolProbity score                   2.15                         
    Clashscore                         5.96                         
    Poor rotamers (%)                  4.94                         
  Ramachandran plot                                                 n/a
    Favored (%)                        95.65                        
    Allowed (%)                        100                          
    Disallowed (%)                     0                            
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![Filamentous tau pathology of Pick's disease.\
**a,** The brain used for cryo-EM (patient 4) showed atrophy of anterior frontal and temporal lobes of the cerebral cortex. Scale bar, 5 cm. **b-d,** Staining of Pick bodies in the frontotemporal cortex of patient 4 by antibody RD3 (3R tau; brown) (**b**), but not by antibodies Anti-4R (4R tau) (**c**) or 12E8 (pS262 tau and/or pS356 tau) (**d**). Nuclei were counterstained blue. Scale bars, 20 μm. **e,** Cryo-electron micrograph of tau filaments extracted from grey matter of the frontotemporal cortex of patient 4, in which narrow (NPFs; blue arrow) and wide (WPFs; red arrow) Pick filaments could be distinguished. Scale bar, 500 Å. **f,** Unsharpened cryo-EM density of NPF from patient 4. Scale bar, 25 Å. **g,** Unsharpened cryo- EM density of WPF from patient 4. Scale bar, 25 Å.](nihms-1500333-f0001){#F1}

![The Pick tau filament fold.\
**a,** Sharpened, high-resolution cryo-EM map of the narrow Pick filament (NPF) with the atomic model of the Pick fold overlayed. **b**, Schematic view of the Pick fold. Amino acid numbering corresponds to the 441 amino acid human tau isoform, so residues 275--305 of R2 are not present.](nihms-1500333-f0002){#F2}

![Comparison of the Pick and Alzheimer tau filament folds.\
**a,** Sequence alignment of the microtubule-binding repeats (R1-R4) with the observed nine β-strand regions (arrows) in the Pick fold and eight β-strand regions (arrows) in the Alzheimer fold, coloured from violet to red. **b,** Rendered view of the secondary structure elements in the Pick fold, depicted as three successive rungs. **c,** As in b, but in a view perpendicular to the helical axis, revealing the changes in height within a single molecule. **d,** Schematic of the secondary structure elements in the Pick and Alzheimer folds, depicted as a single rung. The positions of C322 and D348 in the two folds are highlighted. The symbols ‡ and \* mark conserved turns of homologous regions in the Pick and Alzheimer folds.](nihms-1500333-f0003){#F3}
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